Literature DB >> 26342562

A distinct gene expression signature characterizes human neuroblastoma cancer stem cells.

Robert A Ross1, Jeanette D Walton2, Dan Han3, Hong-Fen Guo4, Nai-Kong V Cheung4.   

Abstract

Neuroblastoma, a malignancy of multipotent embryonic neural crest cells, is the most common extracranial solid cancer in childhood and most common cancer in infancy. Cellular phenotype has been shown to be an important determinant of the malignant potential in human neuroblastoma cells and tumors. Whereas neuroblastic (N-type) are moderately malignant and nonneuronal (S-type) cells are nonmalignant, I-type stem cells are highly tumorigenic, irrespective of N-myc amplification status. In the present study, we sought to determine which genes were overexpressed in the I-type cells which might characterize and maintain the stem cell state and/or malignancy of human neuroblastoma cancer stem cells. We used a microarray platform to compare the steady-state expression levels of mRNAs from 13 human neuroblastoma cell lines representing the three cellular phenotypes. Using qRT-PCR and Western blot analyses, we identified seven genes whose expression is consistently elevated exclusively in neuroblastoma cancer stem cells: CD133, KIT, NOTCH1, GPRC5C, PIGF2, TRKB, and LNGFR. Moreover, we show that the genes are phenotype specific, as differentiation of I-type BE(2)-C cells to either an N- or S-type morphology results in significantly reduced mRNA expression. Finally, we show that NOTCH1 plays an important role in maintaining the stem cell phenotype. The identification and characterization of these genes, elevated in highly malignant neuroblastoma stem cells, could provide the basis for developing novel therapies for treatment of this lethal childhood cancer.
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  Differentiation; GPRC5C; Neuroblastoma; Neurotrophic receptors; Notch1; Placental growth factor-2; Stem cell

Mesh:

Substances:

Year:  2015        PMID: 26342562      PMCID: PMC4601571          DOI: 10.1016/j.scr.2015.08.008

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  47 in total

Review 1.  Neurotrophins: roles in neuronal development and function.

Authors:  E J Huang; L F Reichardt
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

Review 2.  Human neuroblastoma stem cells.

Authors:  Robert A Ross; Barbara A Spengler
Journal:  Semin Cancer Biol       Date:  2006-05-17       Impact factor: 15.707

3.  CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway.

Authors:  Hervé Sartelet; Tina Imbriglio; Carine Nyalendo; Elie Haddad; Borhane Annabi; Michel Duval; Raouf Fetni; Kokta Victor; Lubo Alexendrov; Daniel Sinnett; Monique Fabre; Gilles Vassal
Journal:  Histopathology       Date:  2012-03-06       Impact factor: 5.087

4.  CD133 suppresses neuroblastoma cell differentiation via signal pathway modification.

Authors:  H Takenobu; O Shimozato; T Nakamura; H Ochiai; Y Yamaguchi; M Ohira; A Nakagawara; T Kamijo
Journal:  Oncogene       Date:  2010-09-06       Impact factor: 9.867

5.  Neuroprotection by PlGF gene-modified human mesenchymal stem cells after cerebral ischaemia.

Authors:  H Liu; O Honmou; K Harada; K Nakamura; K Houkin; H Hamada; J D Kocsis
Journal:  Brain       Date:  2006-08-10       Impact factor: 13.501

6.  Molecular cloning and characterization of two novel retinoic acid-inducible orphan G-protein-coupled receptors (GPRC5B and GPRC5C).

Authors:  M J Robbins; D Michalovich; J Hill; A R Calver; A D Medhurst; I Gloger; M Sims; D N Middlemiss; M N Pangalos
Journal:  Genomics       Date:  2000-07-01       Impact factor: 5.736

7.  Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.

Authors:  Katherine K Matthay; C Patrick Reynolds; Robert C Seeger; Hiroyuki Shimada; E Stanton Adkins; Daphne Haas-Kogan; Robert B Gerbing; Wendy B London; Judith G Villablanca
Journal:  J Clin Oncol       Date:  2009-01-26       Impact factor: 44.544

8.  Expression and clinical significance of stem cell marker CD133 in human neuroblastoma.

Authors:  Qiang-Song Tong; Li-Duan Zheng; Shao-Tao Tang; Qing-Lan Ruan; Yuan Liu; Shi-Wang Li; Guo-Song Jiang; Jia-Bin Cai
Journal:  World J Pediatr       Date:  2008-02       Impact factor: 2.764

9.  Anti-chemorepulsive effects of vascular endothelial growth factor and placental growth factor-2 in dorsal root ganglion neurons are mediated via neuropilin-1 and cyclooxygenase-derived prostanoid production.

Authors:  Lili Cheng; Haiyan Jia; Marianne Löhr; Azadeh Bagherzadeh; David I R Holmes; David Selwood; Ian Zachary
Journal:  J Biol Chem       Date:  2004-05-04       Impact factor: 5.157

10.  Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group.

Authors:  P S Cohen; J P Chan; M Lipkunskaya; J L Biedler; R C Seeger
Journal:  Blood       Date:  1994-11-15       Impact factor: 22.113

View more
  22 in total

1.  Getting down to the FACT: therapeutic targeting of MYC-dependent tumors.

Authors:  Monica Venere
Journal:  Ann Transl Med       Date:  2017-04

2.  An overview of neuroblastoma cell lineage phenotypes and in vitro models.

Authors:  Sheron Campos Cogo; Thatyanne Gradowski Farias da Costa do Nascimento; Fernanda de Almeida Brehm Pinhatti; Nilton de França Junior; Bruna Santos Rodrigues; Luciane Regina Cavalli; Selene Elifio-Esposito
Journal:  Exp Biol Med (Maywood)       Date:  2020-08-12

3.  Bottom up proteomics reveals novel differentiation proteins in neuroblastoma cells treated with 13-cis retinoic acid.

Authors:  Effie G Halakos; Andrew J Connell; Lisa Glazewski; Shuo Wei; Robert W Mason
Journal:  J Proteomics       Date:  2019-08-28       Impact factor: 4.044

Review 4.  Cancer Stem Cells and Neuroblastoma: Characteristics and Therapeutic Targeting Options.

Authors:  Veronica Veschi; Francesco Verona; Carol J Thiele
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-19       Impact factor: 5.555

5.  Overexpression of INSM1, NOTCH1, NEUROD1, and YAP1 genes is associated with adverse clinical outcome in pediatric neuroblastoma.

Authors:  Jasna Metovic; Francesca Napoli; Simona Osella-Abate; Luca Bertero; Cristian Tampieri; Giulia Orlando; Maurizio Bianchi; Diana Carli; Franca Fagioli; Marco Volante; Mauro Papotti
Journal:  Virchows Arch       Date:  2022-09-19       Impact factor: 4.535

Review 6.  The "neuro" of neuroblastoma: Neuroblastoma as a neurodevelopmental disorder.

Authors:  Nancy Ratner; Garrett M Brodeur; Russell C Dale; Nina F Schor
Journal:  Ann Neurol       Date:  2016-04-30       Impact factor: 10.422

7.  Stem Cell Markers in Neuroblastoma-An Emerging Role for LGR5.

Authors:  Helen Forgham; Darren Johnson; Noel Carter; Stephany Veuger; Jane Carr-Wilkinson
Journal:  Front Cell Dev Biol       Date:  2015-12-02

8.  Efficient Killing of High Risk Neuroblastoma Using Natural Killer Cells Activated by Plasmacytoid Dendritic Cells.

Authors:  Martine Cordeau; Assila Belounis; Martin Lelaidier; Paulo Cordeiro; Hervé Sartelet; Sabine Herblot; Michel Duval
Journal:  PLoS One       Date:  2016-10-07       Impact factor: 3.240

9.  PlGF and VEGF-A Regulate Growth of High-Risk MYCN-Single Copy Neuroblastoma Xenografts via Different Mechanisms.

Authors:  Karin Zins; Daniel Kovatchki; Trevor Lucas; Dietmar Abraham
Journal:  Int J Mol Sci       Date:  2016-09-23       Impact factor: 5.923

10.  Vascularized Tissue-Engineered Model for Studying Drug Resistance in Neuroblastoma.

Authors:  A Villasante; K Sakaguchi; J Kim; N K Cheung; M Nakayama; H Parsa; T Okano; T Shimizu; G Vunjak-Novakovic
Journal:  Theranostics       Date:  2017-09-21       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.